How to Choose a US Agent for FDA Medical Device Registration?

Overview

For medical device registration with the FDA (510(k) or PMA), non-US manufacturers must designate a US Agent. The agent serves as the official liaison between the manufacturer and the FDA, responsible for receiving communications, adverse event reports, and representing the manufacturer in regulatory matters. Choosing the right agent is critical—one that possesses FDA regulatory knowledge, strong communication skills, and a proven track record. Manufacturers should prioritize professional regulatory service companies with device registration experience and familiarity with product classification and review processes, rather than virtual agents that only provide an address. The agent contract must clearly define responsibilities, response times, change notification obligations, and termination clauses. Common risks include non-cooperation leading to missed FDA deadlines or failure to update agent changes, resulting in registration lapses. Manufacturers should verify the agent's FDA registration records, client references, and team qualifications, and test communication efficiency early in the partnership. Agent services should also be integrated into the quality management system with regular communication mechanisms established.

Key Considerations for Selecting a US Agent

When evaluating a US Agent, manufacturers should assess the following criteria:

• FDA Regulatory Knowledge: The agent must interpret FDA regulations, prepare responses, and track registration status.
• Communication Ability: Ability to represent the manufacturer in formal FDA communications and handle urgent matters.
• Reputation and Track Record: Verify through FDA registration records, client references, and case studies.
• Post-Market Support: Capability to assist with annual registration renewals, listing changes, MDR reports, and recall management.
• Responsiveness: Ensure the agent can meet FDA response deadlines and provide timely updates.

Applicable Scenarios and Core Issues

All non-US manufacturers of FDA-regulated medical devices (Class I, II, III) must designate a US Agent. This requirement applies regardless of the registration pathway (510(k), PMA, De Novo). The core issue is selecting an agent that not only meets legal requirements but actively helps reduce regulatory risks. Many manufacturers mistakenly view the agent as merely a mailing address, but the agent must also interpret regulations, assist in preparing response documents, and monitor registration status. An inadequate agent can lead to unanswered FDA communications, registration lapses, or import refusals.

Registration Judgment Logic

Before selecting an agent, manufacturers should determine their product's regulatory classification and registration path:

• Step 1: Confirm if the product is a medical device under FDA jurisdiction (e.g., software, IVDs).
• Step 2: Determine product classification (Class I/II/III) and whether 510(k), PMA, or exemption applies.
• Step 3: For 510(k), identify a predicate device and assess gaps in technical documentation (performance testing, biocompatibility, software validation).
• Step 4: Ensure the manufacturer has a quality management system compliant with 21 CFR 820 (QSR) or ISO 13485, and prepare the US Agent designation.

For companies registering in multiple countries, evaluate whether existing documents (e.g., ISO 14971 risk management, IEC 60661 safety testing) can be reused, but note that FDA requires specific standards (e.g., UL standards). A qualified agent can identify these differences and guide document adaptation.

Required Documents and Evidence

Manufacturers should provide the following to prospective agents for evaluation:

• Product labeling and instructions for use (English, FDA-compliant)
• Existing technical files (design history, performance testing, risk management reports)
• Quality management system certificates (ISO 13485 or MDSAP)
• Market history (CE certificates, other country registrations)
• Manufacturer information (FEI number, DUNS number, US contact)

Agents should demonstrate their capability with:

• FDA registration account (Industry Registration) screenshot
• Past successful representation cases (client list, product types, outcomes)
• Team qualifications (RAC certification, legal licenses)
• Sample service agreement (response times, change notification, fees)
• Client testimonials or independent evaluations

Common Mistakes and Risks

• Choosing an agent that provides only an address without substantive regulatory support, leading to delayed or missed FDA responses.
• Contract lacks change notification obligations; changing agents without updating the FDA results in registration lapse.
• Agent unfamiliar with FDA electronic submission systems (eSubmitter, CDRH Portal), causing format errors or omissions.
• Ignoring post-market capabilities, such as handling MDRs or recalls.
• Failing to integrate agent services into the quality management system at the manufacturer's end.

Recommended Preparation Checklist

• Confirm FDA requirements: 21 CFR 807.40 for US Agent.
• Define selection criteria: Regulatory knowledge, responsiveness, industry experience, cost.
• Shortlist candidates: Collect qualification documents.
• Conduct background checks: Verify agent's FDA registration status via FDA databases; contact references.
• Test communication: Send mock questions to gauge response accuracy and timeliness.
• Sign service agreement: Include scope of work, confidentiality, change notification, termination, fees.
• Update QMS: Incorporate agent role into supplier management.
• Establish regular meetings (e.g., quarterly) and emergency contact procedures.
• Annual review: Evaluate agent performance and document.

AIMEILI Regulatory Interpretation and Business Impact

Based on our experience serving hundreds of manufacturers, the most common mistake is treating the US Agent as a mere document mailbox, underestimating its critical role in registration compliance. In reality, the agent is the statutory bridge between the manufacturer and FDA; its expertise directly impacts registration progress and post-market compliance risk. Early in the project, manufacturers should prioritize product classification and gap analysis to determine the required technical documentation, then select an agent appropriate for the product's risk level. For example, Class III devices or PMA pathways demand an agent with clinical trial and PMOA experience, while Class I exempt products may only need basic submission services. Core technical files (e.g., risk management, software validation) can often be reused, but labeling must be localized in English and comply with FDA formatting. A qualified local agent should provide localization guidance, including units of measure, warnings, and symbols.

Important: Control over account credentials is critical. While the FDA registration number and listing information belong to the manufacturer, the agent typically holds account passwords. Manufacturers must ensure the agent surrenders account control unconditionally upon change; otherwise, registration may be locked. Similarly, timely renewal (annual registration) and updates (address, product additions) must be performed by the agent to avoid expiration.

For multi-country registrations (e.g., GHWP, Southeast Asia, Latin America), a unified core technical document library managed by the same regulatory team reduces duplication and correction risks. The agent should be able to coordinate localization requirements across different markets.

Frequently Asked Questions

Must the US Agent be a US citizen or permanent resident?

No. FDA only requires the agent to be located in the United States with a physical business address. Citizenship is not required. The agent can be a US company, law firm, or individual, but must be capable of responding to FDA communications promptly.

What if the agent is uncooperative or unreachable?

The manufacturer should immediately invoke the contract's change clause, terminate the existing agent, appoint a new one, and submit an FDA Registration and Listing Update to change agent information. During the transition, a temporary authorized representative (e.g., a US-based employee) can be designated to avoid disruption.

How are agent fees typically structured?

Fees are usually charged annually, covering basic services like registration maintenance, listing updates, and annual reports. Complex services (e.g., 510(k) application support, MDR reporting) are billed separately. Fees range from a few hundred dollars (basic agent) to tens of thousands (full-service package), depending on product risk level and service depth.

Compiled from AIMEILI regulatory practice database, international medical device registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and product documentation.